CAS: 31458-33-0; 5-Methoxypyrimidine

该化合物是一种环环生物化合物,在5号位置用一个甲基氧基集团取代一个火水晶环,这种结构具有独特的再活性和多功能性,使它成为制药和农用化学合成中有价值的中间体.其富含电子的铁质基可促进核生殖性替代反应,使各种功能组得以引入.甲基氧基替代成分在进一步衍生方面增强了稳定性和影响再选择性.通常用于制作活性药物成分和特殊化学物质,5-甲基苯丙胺因其与一系列合成方法的兼容性而得到使用.由于对湿度和空气的敏感性,它通常在不热的条件下处理.

英文名称5-Methoxypyrimidine
中文名称5-甲氧基嘧啶
IUPAC名称5-methoxypyrimidine
其它别名5-Methoxypyrimidine; Pyrimidine, 5-Methoxy- (6Ci,7Ci,8Ci,9Ci); Pyrimidine, 5-Methoxy-; 2-Fluor-3-Methoxy Benzoic Acid; Jiadelsannmyfc-Uhfffaoysa-N; A5
CAS编号31458-33-0
MFCD编号:MFCD04971313
分子式:C5H6N2O
分子量:110.11
产品CID: 1304070
产品分类有机原料→分子砌块→芳杂环类化合物→嘧啶类化合物

相似结构搜索
InChIKey: JIADELSANNMYFC-UHFFFAOYSA-N
InChI=1S/C5H6N2O/c1-8-5-2-6-4-7-3-5/h2-4H,1H3…
计算化学: 氢键受体数3.0氢键供体数0.0可旋转键数1.0

相似化合物

1782399-94-3 26456-59-7 22536-65-8

MSDS等安全信息

GHS符号GHS02,GHS07
警示词Danger
危险描述H228-H302
防范说明P210-P240-P241-P280-P370+P378
危险等级4.1
UN编号1325.0
危险品标志F+
包装等级Ⅲ
安全声明H303+H313+H333

上下游产品

合成工艺路线路线简述

5-溴嘧啶置于sodium体系中,用甲醇作为反应溶剂,以86%的收率获得产物5-甲氧基嘧啶
参考文献:Amino-Pyridines As Inhibitors Of Beta-Secretase
标题:Amino-Pyridines As Inhibitors Of Beta-Secretase
摘要:本发明提供了一种化学式i的氨基吡啶化合物.本发明还提供了利用该化合物抑制β-分泌酶(bace)并治疗β-淀粉样沉积和神经原纤维缠结的方法.

海关参考信息

2905110000-甲醇
2909199090-其他醚及其衍生物
💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
详情请参考：📖 海关编码查询和海关进出口税则

专利信息

专利号:US-2007275962-A1
优先权日:2003-09-10
标题:Heterobicyclic Compounds as Pharmaceutically Active Agents
发明人：KOUL ANIL; KLEBL BERT; MULLER GERHARD; MISSIO ANDREA; SCHWAB WILFRIED; HAFENBRADL DORIS; NEUMANN LARS; SOMMER MARC-NICOLA; MULLER STEFAN; HOPPE EDMUND; FREISLEBEN ACHIM; BACKES ALEXANDER; HARTUNG CHRISTIAN; FELBER BEATRICE; ZECH BIRGIT; ENGKVIST OLA; KERI GYORGY; ORFI LASZLO; BANHEGYI PETER; GREFF ZOLTAN; HORVATH ZOLTAN; VARGA ZOLTAN; MARKO PETER; PATO JANOS; SZABADKAI ISTVAN; SZEKELYHID ZSOLT; WACZEK FRIGYES
权利人:GPC BIOTECH AG
摘要:Described are heterobicyclic compounds such as 4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxylic acid amides, 4,7-dihydro-5H-thieno[2,3-c]thiopyran 3-carboxylic acid amides, 4,7-dihydro-5H-thieno[2,3-c]pyran-3-carboxylic acid amides, or benzo[b]thiophene-3-carboxylic acid amides and pharmaceutically acceptable salts thereof, the use of these derivatives for the prophylaxis and/or treatment of various diseases such as infectious diseases, including mycobacteriainduced infections and opportunistic diseases, prion diseases, immunological diseases, autoimmune diseases, bipolar and clinical disorders, cardiovascular diseases, cell proliferative diseases, diabetes, inflammation, transplant rejections, erectile dysfunction, neurodegenerative diseases and stroke, as well as compositions containing at least one heterobicyclic compound and/or pharmaceutically acceptable salts thereof. Furthermore, reaction procedures for the synthesis of the heterobicyclic compound are disclosed.